Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

AC-220 well tolerated in phase I acute myeloid leukemia study

Dec. 27, 2007

FDA issues nonapprovable letter for Pharmacyclics' NDA for Xcytrin for NSCLC brain metastases

Dec. 24, 2007

Exelixis submits data report for IND candidate XL-139 to Bristol-Myers Squibb

Dec. 24, 2007

Sunesis and the MMRC enter into collaboration to study SNS-032 in multiple myeloma

Dec. 24, 2007

CuraGen and TopoTarget initiate phase II clinical trial of belinostat

Dec. 24, 2007

Encouraging results seen with bevacizumab in glioblastoma multiforme

Dec. 24, 2007

Ongoing phase I/II study reveals activity of ABT-263 in lymphoid malignancies

Dec. 24, 2007

New oncolytic agents disclosed in recent patent literature

Dec. 24, 2007

Positive preclinical results of SB-939 in hematological cancer models

Dec. 24, 2007

FDA issues nonapprovable letter for Indevus' Valstar

Dec. 21, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...